The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 1,554 | 1,483 | -1,927 | -4,157 |
| Stock-based compensation | 1,518 | 1,124 | 1,092 | 3,296 |
| Depreciation and amortization | 1,131 | 1,017 | 1,009 | 2,018 |
| Inventory step-up | 350 | 1,421 | 1,324 | 2,349 |
| Excess and obsolete inventory reserve | 227 | 594 | - | - |
| Debt discount amortization and non-cash interest expenses | 118 | 175 | 179 | 342 |
| Non-cash lease expense | 9 | 9 | 5 | 30 |
| Other operating activity | -7 | - | - | - |
| Accounts receivable | 1,651 | -1,325 | -1,371 | 9,092 |
| Inventories | -1,406 | 581 | -5,614 | 10,909 |
| Prepaid expenses and other assets | -1,754 | 2,521 | 122 | -672 |
| Accounts payable | 2,508 | -3,284 | 2,122 | 7,970 |
| Accrued medicaid rebates | 1,824 | -8,714 | 1,806 | 9,359 |
| Accrued liabilities | -1,532 | 426 | 1,786 | -1,201 |
| Other non-current assets and liabilities | 1,818 | 4,025 | 2,233 | -9,372 |
| Acquisition of business | - | 0 | - | - |
| Net cash from operating activities | 7,405 | -11,551 | 12,026 | 10,049 |
| Purchases of product license rights | 15,000 | 0 | 0 | 0 |
| Purchases of property and equipment | 75 | 49 | 284 | 0 |
| Net cash used in investing activities | -15,075 | -49 | -284 | 0 |
| Net proceeds from the issuance of long-term debt | - | 0 | - | - |
| Repayment of long-term debt | - | 0 | 0 | 0 |
| Common stock issued in private placement offering | - | 0 | - | - |
| Proceeds from stock option exercises | - | 598 | - | - |
| Payment of tax withholding related to net share settlement of stock option exercises | - | 0 | - | - |
| Proceeds from stock option exercises | 1,389 | -177 | 0 | 394 |
| Net cash from financing activities | 1,389 | 421 | 0 | 394 |
| Change in cash and cash equivalents | -6,281 | -11,179 | 11,742 | 10,443 |
| Cash and cash equivalents at beginning of period | 25,942 | 37,121 | 14,936 | - |
| Cash and cash equivalents at end of period | 19,661 | 25,942 | 37,121 | - |
Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc. (ETON)